ScholarIQanswers from OpenAlex & ORCID
Frank V. Fossella
ResearcherPublications, citations & collaboration network
Frank V. Fossella is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Frank V. Fossella have?
ScholarIQindexed works
Frank V. Fossella has 313 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Frank V. Fossella have?
ScholarIQcitation count
Frank V. Fossella has 20,744 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Frank V. Fossella?
ScholarIQh-index
Frank V. Fossella has an h-index of 63 in OpenAlex.
What is the i10-index of Frank V. Fossella?
ScholarIQi10-index
Frank V. Fossella has an i10-index of 151 in OpenAlex.
What is the OpenAlex record for Frank V. Fossella?
ScholarIQopenalex
The OpenAlex for Frank V. Fossella is on the source record.
What are the most-cited papers on Frank V. Fossella?
ScholarIQmost cited works
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo de Marinis, Joachim von Pawel, U. Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Müller, Hong-Liang Lim, Christopher E. Desch, Klára Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, David J. Stewart, Marshall E. Hicks, Jeremy J. Erasmus, Sanjay Gupta, Christine Alden, Suyu Liu, Ximing Tang, Fadlo R. Khuri, Hai T. Tran, Bruce E. Johnson, John V. Heymach, Li Mao, Frank V. Fossella, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Suzanne E. Davis, Scott M. Lippman, Waun Ki Hong
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone, William N. William, Annikka Weissferdt, Cheuk Hong Leung, Heather Lin, Apar Pataer, Myrna C. B. Godoy, Brett W. Carter, Lorenzo Federico, Alexandre Reuben, M.A. Wadud Khan, Hitoshi Dejima, Alejandro Francisco‐Cruz, Edwin R. Parra, Luisa M. Solis, Junya Fujimoto, Hai T. Tran, Neda Kalhor, Frank V. Fossella, Frank E. Mott, Anne S. Tsao, George Blumenschein, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M. Kurie, Mehmet Altan, Charles Lu, Bonnie S. Glisson, Lauren A. Byers, Yasir Y. Elamin, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Jack A. Roth, Mara B. Antonoff, Humam Kadara, Cara Haymaker, Chantale Bernatchez, Nadim J. Ajami, Robert R. Jenq, Padmanee Sharma, James P. Allison, P. Andrew Futreal, Jennifer A. Wargo, Ignacio I. Wistuba, Stephen G. Swisher, J. Jack Lee, Don L. Gibbons, Ara A. Vaporciyan, John V. Heymach, Boris Sepesi
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljević, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, D. Bisset, R. Rosell
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Stephen G. Swisher, Jack A. Roth, John Nemunaitis, D D Lawrence, B L Kemp, C. Humberto Carrasco, D. G. Connors, Adel K. El‐Naggar, Frank V. Fossella, Bonnie S. Glisson, Waun Ki Hong, Fadlo R. Khuri, Jonathan M. Kurie, J. J. Lee, J. S. Lee, Michael J. Mack, James A. Merritt, Dao Nguyen, Jonathan C. Nesbitt, Román Pérez-Soler, K. M. W. Pisters, Joe B. Putnam, William R. Richli, Michael A. Savin, David S. Schrump, Dong M. Shin, Allan N. Shulkin, G. Walsh, Juliette Wait, David Weill, Martin Waugh